Table 1.
Clinical characteristics of CML patients
| Clinical characteristics | CML patients | P value | |
|---|---|---|---|
| IM Responders (n = 27) | IM non‐responders (n = 32) | ||
| Gender | |||
| Male, n | 13 | 18 | .543 |
| Female, n | 14 | 14 | |
| Age at diagnosis (y), mean ± S.D | 50.22 ± 15.23 | 48.53 ± 11.54 | .630 |
| Transcript type | |||
| b2a2, N | 8 | 12 | .390 |
| b3a2, N | 23 | 13 | .006 |
| b2a2 + b3a3, N | 0 | 3 | .540 |
| Sokal score | |||
| Low, N | 8 | 13 | .540 |
| Intermediate, N | 13 | 19 | .470 |
| High, N | 6 | 0 | .190 |
| Achievement of CCyR within 6 mo, N | — | 14 | — |
| Treated with dasatinib, N | — | 11 | — |
| Treated with nilotinib, N | — | 21 | — |
| Primary failure of IM, N | — | 26 | — |
| Secondary failure of IM, N | — | 6 | — |
Abbreviations: CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; IM, imatinib.